Phase 2 N=133 Behavioral Economic Analysis of Demand for Marijuana
Marijuana Smoking
Primary: Validity of the Marijuana Purchase Task (MPT) — 63 percentage of participants — p=.00000004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=28 The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial
Sleep Disturbance · Craving · Cortisol; Hypersecretion
Primary: Change in Total Sleep Time as Measured by Actigraphy and Sleep Logs Relative to Baseline Over the Course of 7 Days of Treatment With Suvorexant in Substance Use Disorder…
N/A N=148 Nexplanon Application Post-Abortion (NAPA)
Contraception · Abortion, Therapeutic
Primary: Intention-to-treat Analysis of Etonogestrel Implant Use — 40; 19; 3; 3 Participants
N/A N=812 Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
N/A N=20 The Project Wellness Pilot Feasibility Randomized Controlled Trial
Diabetes, Gestational
Primary: Change in Self-reported Physical Activity (Assessed by Pregnancy Physical Activity Questionnaire) From Baseline to Follow-up — 0.22; -0.70 MET hours per week
N/A N=1,277,747 COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
N/A N=384 Telemedicine Enhanced Asthma Management Through the Emergency Department
Asthma
Primary: Number of Symptom-Free Days in the Prior 2 Weeks — 9.5; 10.1 days
Phase 1 N=12 Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Pregnancy · Contraception
Primary: Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1 — 0.36; 0.67 nanograms (ng)/milliliter (mL)
N/A N=105 Abbott Next Generation Drug Eluting Stent 48mm Study
Coronary Artery Disease
Primary: Kaplan-Meier Estimate of 1-Year Target Lesion Failure (TLF) — 5.7 Percentage of events — p=<0.0001
N/A N=27 Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial
Breast Cancer · Invasive Breast Carcinoma
Primary: Intervention Feasibility — 1; 3; 8; 6 Participants
N/A N=36 PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
Diabetes Mellitus · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Accuracy of CGM System Through 90 Days Post-Insertion (MARD for Paired CGM and Reference Glucose Measurements) — 9.6 percent
Phase 1 N=45 Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
Covid19 · Severe Acute Respiratory Syndrome · SARS-CoV-2 Infection
Primary: Number of at Least Possibly Related Grade 3 Adverse Events (AE) and Serious Adverse Events (SAE) — 0; 1; 0; 0 adverse events
N/A N=26,774 A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
Diabetes Mellitus, Type 2
Primary: Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis — 36.1; 35.9 Events per 1000 person-years
N/A N=56 Ear Acupuncture for Acute Sore Throat.
Acute Sore Throat
Primary: Reduction in Pain — 6.4; 6.2; 2.6; 6.0 score on a scale
N/A N=400 POLARx Cardiac Cryoablation System Study
Atrial Fibrillation
Primary: Safety Event Free Rate — 373 Participants